WilmerHale Advises Thermo Fisher on its CHF 1.425 Billion Offering of Bonds

WilmerHale Advises Thermo Fisher on its CHF 1.425 Billion Offering of Bonds

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.

WilmerHale acted as US special counsel to Thermo Fisher Scientific Inc. in connection with its offer and sale of CHF-denominated bonds, in an offering that was the largest Swiss franc bond issuance from a US corporate issuer in history. The offering consisted of CHF 410,000,000 aggregate principal amount of 0.8320% Bonds due 2026, CHF 315,000,000 aggregate principal amount of 1.1250% Bonds due 2029, CHF 350,000,000 aggregate principal amount of 1.4175% Bonds due 2033, CHF 215,000,000 aggregate principal amount of 1.6524% Bonds due 2037 and CHF 135,000,000 aggregate principal amount of 1.8975% Bonds due 2045, each to be listed on the SIX Swiss Exchange. The offering priced on February 26, 2025 and closed on March 7, 2025. UBS AG, acting through its business division, UBS Investment Bank, BNP Paribas (Suisse) SA and Deutsche Bank AG London Branch, acting through Deutsche Bank AG Zurich Branch, acted as the joint lead managers for the offering.

The WilmerHale team advising Thermo Fisher Scientific Inc. on the offering consisted of Molly Fox, Andrew Langworthy, Rachael Joseph and Tim Kolankowski (Capital Markets), with assistance from Meghan Walsh and Benjamin Kelsey (Tax).

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel